Drug Profile
Pamiteplase
Alternative Names: Solinase; YM 22866; YM 866Latest Information Update: 11 Apr 2005
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Myocardial infarction
- Discontinued Stroke
Most Recent Events
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
- 13 May 2004 Discontinued - Phase-II for Stroke in Japan (Injection)
- 20 Oct 2003 This compound is still in active development